Filing Flows › Organogenesis Holdings (ORGO) › Q1 2026
Organogenesis Holdings (ORGO) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Organogenesis Holdings (ORGO) reported revenue of $37.2M for the first quarter 2026 (Q1 2026), -57% from a year earlier and -83% from the quarter before. Operating margin was -185.1%, net loss $53.2M (142.8% of revenue).
Organogenesis Holdings, Q1 2026: revenue $37.2M (-57% year over year), operating margin -185.1%, net loss $53.2M, operating cash flow $21.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $37.2M | -83% | -57% |
| Operating profit | −$68.9M | -209% | — |
| Net earnings | −$53.2M | -222% | — |
| Operating cash flow | $21.1M | -46% | — |
| Free cash flow | $18.0M | -48% | — |
What changed
Revenue was $37.2M in Q1 2026, down 57% year over year and down 83% from the previous quarter. Product was the largest line at 97% of revenue. Product lost $50.4M year over year (down 58%), 102% of the total change.
Operating costs exceeded revenue by $68.9M, an operating margin of -185.1%. The fastest-growing cost line was Other operating costs (+292%). The quarter ended with a net loss of $53.2M, after a profit of $43.7M the previous quarter.
Operating cash flow was $21.1M. Non-cash charges added back $4.2M of depreciation and amortization and $3.6M of share-based compensation. Working capital and other items added $66.5M. Capital expenditures of $3.1M left free cash flow of $18.0M.
Questions
What was Organogenesis Holdings' revenue in the first quarter 2026?
Organogenesis Holdings (ORGO) reported revenue of $37.2M for the first quarter 2026 (Q1 2026), -57% from a year earlier and -83% from the quarter before.
Was Organogenesis Holdings profitable in the first quarter 2026?
Operating loss was $68.9M (-185.1% of revenue) and net loss $53.2M.